Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Association between Comorbidities and Progression of Transvalvular Pressure Gradients in Patients with Moderate and Severe Aortic Valve Stenosis.

Salinger T, Hu K, Liu D, Taleh S, Herrmann S, Oder D, Gensler D, Müntze J, Ertl G, Lorenz K, Frantz S, Weidemann F, Nordbeck P.

Cardiol Res Pract. 2018 Nov 11;2018:3713897. doi: 10.1155/2018/3713897. eCollection 2018.

2.

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.

Müntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, Hu K, Lorenz K, Frantz S, Wanner C, Nordbeck P.

Clin Pharmacol Ther. 2019 May;105(5):1224-1233. doi: 10.1002/cpt.1321. Epub 2019 Jan 13.

4.

Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function.

Hu K, Liu D, Salinger T, Oder D, Knop S, Ertl G, Weidemann F, Frantz S, Störk S, Nordbeck P.

J Thorac Dis. 2018 Aug;10(8):4966-4975. doi: 10.21037/jtd.2018.07.56.

5.

Characterization of vertigo and hearing loss in patients with Fabry disease.

Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven SP.

Orphanet J Rare Dis. 2018 Aug 15;13(1):137. doi: 10.1186/s13023-018-0882-7.

6.

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease.

Liu D, Oder D, Salinger T, Hu K, Müntze J, Weidemann F, Herrmann S, Ertl G, Wanner C, Frantz S, Störk S, Nordbeck P.

Open Heart. 2018 Jul 12;5(2):e000803. doi: 10.1136/openhrt-2018-000803. eCollection 2018.

7.

Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation.

Liu D, Hu K, Schmidt M, Müntze J, Maniuc O, Gensler D, Oder D, Salinger T, Weidemann F, Ertl G, Frantz S, Wanner C, Nordbeck P.

Clin Res Cardiol. 2018 Dec;107(12):1111-1121. doi: 10.1007/s00392-018-1285-4. Epub 2018 May 24.

8.

Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study.

Oder D, Liu D, Üçeyler N, Sommer C, Hu K, Salinger T, Müntze J, Petritsch B, Ertl G, Wanner C, Nordbeck P, Weidemann F.

Medicine (Baltimore). 2018 May;97(21):e10669. doi: 10.1097/MD.0000000000010669.

9.

The D313Y genotype-Pathogenic mutation or polymorphism?

Oder D, Wanner C, Nordbeck P.

Clin Genet. 2018 Jun;93(6):1257. doi: 10.1111/cge.13237. Epub 2018 Mar 9. No abstract available.

PMID:
29521444
10.

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM.

J Med Genet. 2018 May;55(5):351-358. doi: 10.1136/jmedgenet-2017-104863. Epub 2018 Feb 7.

11.

Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease.

Köping M, Shehata-Dieler W, Cebulla M, Rak K, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven S.

PLoS One. 2017 Nov 21;12(11):e0188103. doi: 10.1371/journal.pone.0188103. eCollection 2017.

12.

α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.

Oder D, Liu D, Hu K, Üçeyler N, Salinger T, Müntze J, Lorenz K, Kandolf R, Gröne HJ, Sommer C, Ertl G, Wanner C, Nordbeck P.

Circ Cardiovasc Genet. 2017 Oct;10(5). pii: e001691. doi: 10.1161/CIRCGENETICS.116.001691.

PMID:
29018006
13.

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.

Arends M, Biegstraaten M, Hughes DA, Mehta A, Elliott PM, Oder D, Watkinson OT, Vaz FM, van Kuilenburg ABP, Wanner C, Hollak CEM.

PLoS One. 2017 Aug 1;12(8):e0182379. doi: 10.1371/journal.pone.0182379. eCollection 2017.

14.

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.

Guérard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford RWD, Dingemanse J, Wanner C.

Clin Pharmacol Ther. 2018 Apr;103(4):703-711. doi: 10.1002/cpt.790. Epub 2017 Aug 28.

PMID:
28699267
15.

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

Lenders M, Oder D, Nowak A, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E.

J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647. Epub 2017 Jul 26.

PMID:
28682471
16.

[The Fabry's Disease Cardiomyopathy as Differential Diagnosis of Acute Coronary Syndrome].

Oder D, Störk S, Wanner C, Ertl G, Weidemann F, Nordbeck P.

Dtsch Med Wochenschr. 2017 Mar;142(6):442-449. doi: 10.1055/s-0042-118303. Epub 2017 Mar 22. Review. German.

PMID:
28329906
17.

Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.

Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, Elliott PM, Linthorst GE, Wijburg FA, Biegstraaten M, Hollak CE.

J Am Soc Nephrol. 2017 May;28(5):1631-1641. doi: 10.1681/ASN.2016090964. Epub 2016 Dec 15.

18.

Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic Heart Failure Complicated by Significant Functional Tricuspid Regurgitation.

Hu K, Liu D, Störk S, Herrmann S, Oder D, Ertl G, Voelker W, Weidemann F, Nordbeck P.

J Card Fail. 2017 Jun;23(6):434-443. doi: 10.1016/j.cardfail.2016.11.005. Epub 2016 Nov 24.

19.

Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease.

Oder D, Nordbeck P, Wanner C.

Nephron. 2016;134(1):30-6. doi: 10.1159/000448968. Epub 2016 Aug 27. Review.

20.

Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles.

Oder D, Vergho D, Ertl G, Wanner C, Nordbeck P.

BMC Med Genet. 2016 Jul 19;17(1):46. doi: 10.1186/s12881-016-0309-z.

21.

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.

Oder D, Üçeyler N, Liu D, Hu K, Petritsch B, Sommer C, Ertl G, Wanner C, Nordbeck P.

BMJ Open. 2016 Apr 8;6(4):e010422. doi: 10.1136/bmjopen-2015-010422.

22.

Prevention of venous thromboembolism after injury.

Velmahos GC, Kern J, Chan L, Oder D, Murray JA, Shekelle P.

Evid Rep Technol Assess (Summ). 2000 Aug;(22):1-3. No abstract available.

23.

Penetrating trauma in patients older than 55 years: a case-control study.

Roth BJ, Velmahos GC, Oder DB, Vassiliu P, Tatevossian R, Demetriades D, Belzberg H, Alo K.

Injury. 2001 Sep;32(7):551-4.

PMID:
11524087
24.

An evidence-based cost-effectiveness model on methods of prevention of posttraumatic venous thromboembolism.

Velmahos GC, Oh Y, McCombs J, Oder D.

J Trauma. 2000 Dec;49(6):1059-64.

PMID:
11130489
25.
26.

Prevention of venous thromboembolism after injury: an evidence-based report--part I: analysis of risk factors and evaluation of the role of vena caval filters.

Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P.

J Trauma. 2000 Jul;49(1):132-8; discussion 139.

PMID:
10912869
27.

The prevalence and effect of alcohol and drug abuse on cohort-matched critically injured patients.

Cornwell EE 3rd, Belzberg H, Velmahos G, Chan LS, Demetriades D, Stewart BM, Oder DB, Kahaku D, Chan D, Asensio JA, Berne TV.

Am Surg. 1998 May;64(5):461-5.

PMID:
9585786
28.

Use of large databases for resolving critical care problems.

Belzberg H, Murray J, Shoemaker WC, Cornwell EE, Oder D, Guenon J, Velmahos G, Demetriades D.

New Horiz. 1996 Nov;4(4):532-40.

PMID:
8968985
29.

Medical center innovations.

Oder DR.

Rep Natl Forum Hosp Health Aff. 1978:40-9. No abstract available.

PMID:
10261148

Supplemental Content

Support Center